49851-55-0

Basic information

• Product Name: 2-Bromophenacyl bromide, 90%
• Synonyms: 2-Bromo-2'-bromoacetophenone;2-Bromo-1-(2-bromophenyl)ethan-1-one;2-Bromo-1-(2-bromophenyl)ethanone;2-Bromophenacyl bromide;2-Bromo-1-(2-bromophenyl)ethan-1-one, 2,2'-Dibromoacetophenone;2-Bromophenacylbromide90%;2-Bromophenacylbromide97%
• CAS NO: 49851-55-0
• Molecular Formula: C₈H₆Br₂O
• Molecular Weight: 277.94
• Mol File: 49851-55-0.mol
• Article Data: 54

Chemical Properties

• Boiling Point: 90-92°C/0.02mm
• Flash Point: 108.1 °C
• Appearance: /
• Density: 1.848 g/cm³
• Vapor Pressure: 0.00116mmHg at 25°C
• Refractive Index: 1.6100-1.6140
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Sensitive: Lachrymatory
• CAS DataBase Reference: 2-Bromophenacyl bromide, 90%(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromophenacyl bromide, 90%(49851-55-0)
• EPA Substance Registry System: 2-Bromophenacyl bromide, 90%(49851-55-0)

Safety Data

• Hazard Codes: C
• RIDADR: 3261
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 49851-55-0(Hazardous Substances Data)

Usage

Uses

2,2''-Dibromoacetophenone is used in the preparation of 4-phenylthiazol-2(3H)-one derivatives as anticonvulsant agents.

InChI:InChI=1/C8H6Br2O/c9-5-8(11)6-3-1-2-4-7(6)10/h1-4H,5H2

Upstream product

• 2142-69-0 2-bromophenyl methyl ketone 
• 1973-22-4 1-bromo-2-ethylbenzene 
• 6630-33-7 ortho-bromobenzaldehyde 
• 401514-46-3 1-(bromoethynyl)-2-bromobenzene 
• 2039-88-5 2-bromostyrene 
• 88-65-3 2-bromobenzoic-acid 
• 4001-73-4 2-Bromobenzamide 
• 2042-37-7 o-cyanobromobenzene 
• 7154-66-7 2-bromobenzoic acid chloride 
• 46004-44-8 2-bromo-ω-diazoacetophenone 

Downstream Products

• 39166-17-1 6-(2-bromo-phenyl)-4-chloro-5-methyl-5H-pyrimido[4,5-b][1,4]thiazine 
• 171734-91-1 1-<2-(2-bromophenyl)-2-oxoethyl>-1H-indole-3-carboxaldehyde 
• 320371-89-9 1-(2-bromo-phenyl)-2-(4-methoxy-phenoxy)-ethanone 
• 1207477-00-6 C₃₂H₂₄BrN₃O₃ 
• 912654-62-7 (2-bromophenyl)(1H-indol-2-yl)methanone 
• 1393890-93-1 (Z)-5-(4-(2-(2-bromophenyl)-2-oxoethoxy)benzylidene)-2-thioxothiazolidin-4-one 
• 1393891-06-9 (Z)-2-(5-(4-(2-(2-bromophenyl)-2-oxoethoxy)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid 
• 1393891-19-4 (S,Z)-2-(5-(4-(2-(2-bromophenyl)-2-oxoethoxy)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl)-3-phenylpropanoic acid 
• 1393891-32-1 (S,Z)-2-(5-(4-(2-(2-bromophenyl)-2-oxoethoxy)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl)-3-(4-hydroxyphenyl)propanoic acid 
• 1393891-45-6 (S,Z)-2-(5-(4-(2-(2-bromophenyl)-2-oxoethoxy)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl)-3-(1H-indol-3-yl)propanoic acid 
• 1393890-86-2 C₁₅H₁₁BrO₃ 
• 1427763-47-0 2-(2-(1H-imidazol-1-yl)phenyl)imidazo[1,2-a]pyridine 
• 1427763-65-2 6-bromo-2-(2-bromophenyl)-imidazo[1,2-a]pyridine 
• 419557-44-1 2-(2-bromophenyl)-6-methylimidazolo[1,2-a]pyridine 

Relevant articles and documents

Synthesis and anti-methicillin-resistant Staphylococcus aureus activity of 5,7-dibromo-2-benzoylbenzofurans alone and in combination with antibiotics

A series of 5,7-dibromo-2-benzoylbenzofurans were synthesized by the Rap–Stoermer condensation of 5,7-dibromosalicylaldehyde with diverse phenacyl bromides and evaluated for in-vitro antibacterial activities against methicillin-sensitive Staphylococcus aureus (MSSA) ATCC 29213, methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300, and MRSA ATCC 33591 by agar dilution method. The synergistic effects were determined by using the agar dilution checkerboard assay. The derivatives bearing carboxylic acid functional groups exhibited reasonable activity against MRSA strains with the best MIC = 32 μg/mL (9b, 9d). Moreover, the additive or synergistic interactions against MRSA strains was observed in six combinations (1b + cefuroxime/gentamicin, 1c + ciprofloxacin/gentamicin, 9b + gentamicin, and 9c + ciprofloxacin) with the fractional inhibitory concentration index (FICI) values in the range of 0.375–1.0. Significantly, the MICs of these antibiotics were reduced 2–4-fold. The results of the MTT assay illustrated the low mammalian cell cytotoxicity of these potent compounds.

SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

Synthesis of 5-Aryl-5H-pyrido[2',1':2,3]imidazo[4,5-b]indoles by Domino Pd- and Cu-Catalyzed C-N Coupling Reactions

A series of 5-aryl-5H-pyrido[2',1':2,3]imidazo[4,5- b ]indoles was successfully prepared in good yields by a practical four-step strategy. In this procedure, the key step was demonstrated to be the domino Pd-and Cu-catalyzed C-N coupling reactions of 3-br